Alzheimer’s Drug Discovery Foundation

CNS-centric CRO matching service launches

Monday, June 19, 2017

A new matching service has launched for scientists working in the therapeutic area of the central nervous system (CNS) who are ready to move their discoveries from the bench to trials, but have no idea where to turn when it comes to finding and choosing a CRO or lab that knows their therapeutic area well.

[Read More]

Harrington Discovery, ADDF expand collaboration

Friday, January 13, 2017

Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, and the Alzheimer’s Drug Discovery Foundation (ADDF) have expanded their collaboration to accelerate translation of innovative research efforts for Alzheimer’s disease. Together, the two organizations will jointly market and administer a new award program for academic researchers. By leveraging their combined expertise, investment, and resources, Harrington Discovery Institute and the ADDF will advance Alzheimer’s disease drug discovery projects of great promise in academic institutions nationwide.

[Read More]

NIH-led effort launches Big Data portal for Alzheimer’s drug discovery

Friday, March 6, 2015

A NIH-led public-private partnership to transform and accelerate drug development has launched a new Alzheimer’s Big Data portal—including delivery of the first wave of data—for use by the research community. The new data sharing and analysis resource is part of the Accelerating Medicines Partnership (AMP), an unprecedented venture bringing together NIH, FDA, industry and academic scientists from a variety of disciplines to translate knowledge faster and more successfully into new therapies.

[Read More]

ADDF, Alzheimer’s Society U.K. to test erectile dysfunction drug as dementia treatment

Friday, December 12, 2014

The Alzheimer’s Drug Discovery Foundation (ADDF), based in New York, and the Alzheimer’s Society U.K. have announced new funding to explore the possibility of using a commonly prescribed drug which treats erectile dysfunction as the next treatment for dementia. Tadalafil—part of the same class of drugs as Viagra—is to be one of the major research programs funded by the two charities in a cross-Atlantic research partnership. This is the first ever study researching the use of an erectile dysfunction drug for vascular dementia.

[Read More]

Alzheimer’s Drug Discovery Foundation, OnDeckBiotech partner

Friday, June 27, 2014

The Alzheimer’s Drug Discovery Foundation (ADDF) and OnDeckBiotech, a Boston-based software company providing software tools for biotech, pharma and R&D service vendors, are partnering to provide a new platform technology for ADDF ACCESS, an open-access database that provides a network of CROs, drug development consultants and educational resources focused for diseases of the central nervous system (CNS).

[Read More]

ADDF, Alzheimer’s Society partner on $3M initiative

Wednesday, January 29, 2014

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Alzheimer’s Society (U.K.) have partnered to provide funding for research in Alzheimer’s disease and related dementias, with the goal of accelerating critical development programs and bringing new treatments to patients. The partnership intends to fund projects up to $1.5 million each, focused on drug repurposing, leveraging existing scientific evidence and research to accelerate the drug development process.

[Read More]

ADDF, Charles River collaborate in research award program

Wednesday, July 13, 2011

The Alzheimer’s Drug Discovery Foundation (ADDF) is collaborating with Charles River Laboratories International, a provider of early-stage drug development products and services, to create a new research award program entitled Use of Aged Rats as a Relevant Pre-clinical Model for the Development of Therapies for Cognitive Aging and Alzheimer’s Disease.  The program is made possible through a donation from Charles River’s Discovery Services business and funds from the ADDF.

[Read More]